{"id":11329,"date":"2025-07-27T00:26:30","date_gmt":"2025-07-26T22:26:30","guid":{"rendered":"https:\/\/valintermed.com\/?p=11329"},"modified":"2025-07-27T00:26:30","modified_gmt":"2025-07-26T22:26:30","slug":"ganglioneyroblastoma","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/ganglioneuroblastoma\/","title":{"rendered":"Ganglioneuroblastoma"},"content":{"rendered":"
<\/div>\n

Ganglioneuroblastoma (GN) is a rare malignant tumor that develops from neuroblasts, the early cells that predate nerve cells. This disease is most often observed in children, from the neonatal period to 5 years of age. The pathways of ganglioneuroblastoma formation are not yet fully understood, but it is known that this is a dopamine tumor that can affect both the adrenal glands and the sympathetic nervous system. Ganglioneuroblastoma can manifest itself with various clinical symptoms, including abdominal pain, abdominal enlargement, anemia, and weight loss. Due to the fact that the disease can be aggressive, early diagnosis and initiation of treatment are critical for successful control of the pathology.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n